Five Years of Theranostic Services 

August brought up five years of dedicated Theranostics service at Mercy. This journey stands as a testament to our commitment to elevating healthcare standards in New Zealand.

Mercy Theranostic commemorates a remarkable five years of delivering exemplary Theranostics services on 24 August 2023. This milestone is a testament to our unwavering commitment to advancing medical care in New Zealand. Prior to our inception, the dearth of accessible Theranostic services in the country led to a heavy reliance on Australia for such treatments. 

On 24th August 2018, Mercy Radiology pioneered the introduction of Lu177 PSMA treatment revolutionising prostate cancer care and to date, we have enrolled/treated 160+ patients. Notably, we have prepared more than 400 doses of LU177 PSMA and DOTATATE of Lu177, addressing the unique needs of each patient. A hallmark of leadership in the field is the initiation of cutting-edge clinical trials for the New Zealand population, offering state-of-the-art therapeutic and diagnostic services. 

Through these milestones, proudly Mercy has cemented its position as a pioneering force in Theranostics, setting trends, and raising the bar for medical excellence in the region.

We still have a long way to go but we can celebrate our achievements to date and a huge congratulations to all the team members.

Madhusudan Vyas / Jessica Fagan